Nakao Akimasa
Second Department of Surgery, Nagoya Unversity Hospital, Nagoya, Japan.
J Hepatobiliary Pancreat Surg. 2003;10(1):57-60. doi: 10.1007/s10534-002-0801-0.
BACKGROUND/PURPOSE: A clinical study was carried out to clarify the indications for extended resection of pancreatic cancer.
From July 1981 to April 2000, 200 of 314 (63.7%) patients with pancreatic cancer underwent extended tumor resection. Portal vein resection was performed in 146 of the 200 (73%) resected cases. The postoperative survival rate was studied based on the operative and histopathological findings.
Operative death (within 30 days postoperatively) occurred in 11 of the 200 (5.5%) resected patients. Most of the patients who survived for 2 or 3 years were in the group with carcinoma-free surgical margins.
The most important indication for an extended operation combined with portal vein resection for pancreatic cancer is the likelihood of obtaining surgical cancer-free margins. There is no indication for an extended resection inpatients in whom the surgical margins will become cancer-positive if such a resection is employed.
背景/目的：开展一项临床研究以明确胰腺癌扩大切除术的适应证。
1981年7月至2000年4月，314例胰腺癌患者中有200例（63.7%）接受了扩大肿瘤切除术。200例接受切除术的患者中有146例（73%）进行了门静脉切除术。基于手术及组织病理学检查结果研究术后生存率。
200例接受切除术的患者中有11例（5.5%）发生手术死亡（术后30天内）。存活2年或3年的大多数患者处于手术切缘无癌的组中。
胰腺癌扩大手术联合门静脉切除术的最重要适应证是获得无癌手术切缘的可能性。对于采用这种切除术手术切缘将变为癌阳性的患者，没有扩大切除术的适应证。
